Drug intelligence / Profile preview

PF-06263276

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Inhalation, Topical

Overview

PF-06263276 is a small molecule, pan-Janus kinase (JAK) inhibitor developed by Pfizer for inhaled and topical delivery. It was designed using structure-based computational methods to bind beyond the ATP binding site of JAKs, resulting in a type 1.5 binding mode. The drug inhibits multiple JAK isoforms—JAK1, JAK2, JAK3, and TYK2—and was optimized for potency and duration of action suitable for treating inflammatory diseases of the lungs and skin. Clinical development included Phase 1 trials in plaque psoriasis and psoriasis vulgaris.

Targets

TYK2 (Tyrosine kinase 2)JAK2 (Janus kinase 2)JAK1 (Janus kinase 1)JAK3 (Janus kinase 3)

Beyond the preview

Go deeper on PF-06263276.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-06263276.

Explore the full profile